A Multinational, Multicenter, Single Blood Sampling Exploratory Pharmacogenetic Study of the REGARD (the REbif® vs Glatiramer Acetate in Relapsing MS Disease) Trial [SUBSTUDY OF 700004881]

Trial Profile

A Multinational, Multicenter, Single Blood Sampling Exploratory Pharmacogenetic Study of the REGARD (the REbif® vs Glatiramer Acetate in Relapsing MS Disease) Trial [SUBSTUDY OF 700004881]

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2014

At a glance

  • Drugs Interferon beta-1a (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms REGARD-PGx
  • Sponsors EMD Serono
  • Most Recent Events

    • 29 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Dec 2010 Planned end date changed from 1 Oct 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 23 Dec 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top